ClinicalTrials.gg
Active, not recruitingNCT02477696Updated Aug 26, 2026Results posted

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

A Phase 3 interventional study of Acalabrutinib and Ibrutinib in Chronic Lymphocytic Leukemia, sponsored by Acerta Pharma BV. Active, not recruiting at 130 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
533
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 28 under way, 6 of them phase 3. acalabrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
5th of 39
533 · median 61
Started
2015
with 3 others
Phase 3
9 of 39
1 open now
Primary completion
2020-09
later than 1 of 27 live
Registered
4th of 39
by date
Lead sponsor
9 of 39
Acerta Pharma BV

Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 5th largest by enrollment, is one of 4 that started in 2015, is one of 9 in phase 3, reaches primary completion later than 1 of the 27 other live ones, and was the 4th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

11 of the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About acalabrutinib

acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic lymphocytic leukemia.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ≥ 18 years of age.
  • performance status of 0 to 2.
  • Diagnosis of CLL.
  • Must have ≥ 1 of the following high-risk prognostic factors:

    • Presence of 17p del by central laboratory.
    • Presence of 11q del by central laboratory.
  • Active disease meeting ≥ 1 of the following IWCLL 2008 criteria for requiring treatment
  • Must have received ≥ 1 prior therapies for CLL.
  • Meet the following laboratory parameters:

    • (ANC) ≥ 750 cells/μL or ≥ 500 cells/μL in participants with documented bone marrow involvement, and independent of growth factor support 7 days before assessment.
    • count ≥ 30,000 cells/μL without transfusion support 7 days before assessment. Participants with transfusion-dependent thrombocytopenia are excluded.
    • Serum (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT) ≤ 3.0 x (ULN).
    • Total ≤ 1.5 x ULN.
    • Estimated ≥ 30 mL/min.

Exclusion criteria

Exclusion Criteria:

  • Known CNS lymphoma or leukemia.
  • Known prolymphocytic leukemia or history of, or currently suspected, Richter's syndrome.
  • Uncontrolled hemolytic anemia or idiopathic thrombocytopenia purpura.
  • Prior exposure to ibrutinib or to a B-cell receptor (BCR) inhibitor or a B-cell lymphoma-2 (BCL-2) inhibitor.
  • Received any chemotherapy, external beam radiation therapy, anticancer antibodies, or drug within 30 days before first dose of study drug.
  • Prior radio- or toxin-conjugated antibody therapy.
  • Prior allogeneic stem cell or transplant.
  • Major surgery within 4 weeks before first dose of study drug.
  • Prior , except for adequately treated lentigo maligna melanoma, non-melanomatous skin cancer, in situ cervical carcinoma or other malignancy treated with no evidence of active disease > 3 years before Screening and at low risk for recurrence.
  • Significant cardiovascular disease within 6 months of screening.
  • Known history of infection with (HIV).
  • History of stroke or intracranial hemorrhage within 6 months before randomization.
  • History of bleeding diathesis.
  • Requires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists within 7 days of first dose of study drug.
  • Requires treatment with a strong cytochrome P450 3A () inhibitor/inducer.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
533 participants (actual)

Study arms

  • Experimental
    Acalabrutinib

    Participants will receive oral acalabrutinib 100 mg twice daily (BID) until disease progression (PD), or unacceptable toxicity, or other reasons for discontinuation, whichever occurs first.

    Drug: Acalabrutinib

  • Active comparator
    Ibrutinib

    Participants will receive oral ibrutinib 420 mg once daily (QD) until PD, or unacceptable toxicity, or other reasons for discontinuation, whichever occurrs first.

    Drug: Ibrutinib

Interventions

  • Participants will receive oral acalabrutinib as stated in arm description.

    Also known as: ACP-196

  • Participants will receive oral ibrutinib as stated in arm description.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment

    The PFS is defined as the time from date of randomization to the date of first IRC-assessed PD or death due to any cause, whichever occurred first. PD (per International Workshop on Chronic Lymphocytic Leukemia \[iwCLL\] 2008 criteria): Lymphocytes \>= 50% increase over baseline, or \>= 50% increase in lymphadenopathy/hepatomegaly/splenomegaly, or \>= 50% platelets or \> 2 g/dL hemoglobin decreases from baseline secondary to chronic lymphocytic leukemia (CLL). The PFS is assessed using the Kaplan-Meier method.

    Time frame: Baseline (Days -28 to -1) through 55.2 months (maximum observed duration)

Secondary outcomes

  1. Number of Participants With Treatment-emergent Infections Grade >= 3

    Number of participants with treatment-emergent infections Grade \>=3 are reported.

    Time frame: Day 1 through 83.5 months (maximum observed duration)

  2. Number of Participants With Treatment-emergent Richter's Transformation

    Richter's transformation is defined as the occurrence of an aggressive lymphoma in participants with a previous or concomitant diagnosis of CLL. Richter's transformation was assessed by central pathology. Number of participants with treatment-emergent Richter's transformation are reported.

    Time frame: Day 1 through 83.5 months (maximum observed duration)

  3. Number of Participants With Treatment-emergent Atrial Fibrillation

    Number of participants with treatment-emergent atrial fibrillation (including atrial flutter) are reported.

    Time frame: Day 1 through 83.5 months (maximum observed duration)

  4. Overall Survival (OS)

    The OS is defined as the time from date of randomization to date of death due to any cause. The OS is assessed using the Kaplan-Meier method.

    Time frame: Baseline (Days -28 to -1) through 83.7 months (maximum observed duration)

  5. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

    Time frame: Day 1 through 83.5 months (maximum observed duration)

  6. Number of Participants With Treatment-emergent Laboratory Abnormalities

    Number of participants with treatment-emergent laboratory abnormalities are reported. Laboratory abnormality is defined as any abnormal finding during analysis of hematology and serum chemistry.

    Time frame: Day 1 through 83.5 months (maximum observed duration)

  7. Number of Participants With Abnormal Vital Signs Reported as TEAEs

    Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal finding in the vital sign parameters (body temperature, blood pressure, heart rate, and respiratory rate).

    Time frame: Day 1 through 83.5 months (maximum observed duration)

  8. Percentage of Participants With Lymphocytosis

    Percentage of participants with at least one occurrence of treatment-related lymphocytosis defined as an elevation in ALC of \>= 50% compared with baseline and a postbaseline assessment of \> 5000/μL in the peripheral blood are reported.

    Time frame: Day 1 through 83.5 months (maximum observed duration)

  9. Number of Participants With Electrocardiogram (ECG) Abnormality at Baseline

    Number of participants with ECG abnormality at baseline are reported.

    Time frame: Baseline (Days -28 to -1)

  10. Number of Participants With Shift From Baseline to Worst (Grade 3 and 4) Postbaseline in Eastern Cooperative Oncology Group (ECOG) Performance Status

    The ECOG performance status assessed participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (\>50% of waking hours), capable of all self-care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair \>50% of waking hrs; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=death. Number of participants with shift from baseline (Days -28 to -1) to worst Grade 3 and 4 in ECOG performance status are reported.

    Time frame: Baseline (Days -28 to -1) through 83.5 months (maximum observed duration)

07

Results

Posted Jan 28, 2022

Participant flow

Participant flow — Overall Study
MilestoneAcalabrutinibIbrutinib
Started268265
Treated265264
Completed00
Not completed268265
Withdrew: Death89106
Withdrew: Lost to follow-up75
Withdrew: Withdrawal by subject3734
Withdrew: Physician decision79
Withdrew: Study terminated by sponsor10399
Withdrew: Other reasons including transition to commercial drug2312
Withdrew: Missing/unknown20

Outcome measures

PrimaryProgression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment

The PFS is defined as the time from date of randomization to the date of first IRC-assessed PD or death due to any cause, whichever occurred first. PD (per International Workshop on Chronic Lymphocytic Leukemia \[iwCLL\] 2008 criteria): Lymphocytes \>= 50% increase over baseline, or \>= 50% increase in lymphadenopathy/hepatomegaly/splenomegaly, or \>= 50% platelets or \> 2 g/dL hemoglobin decreases from baseline secondary to chronic lymphocytic leukemia (CLL). The PFS is assessed using the Kaplan-Meier method.

Time frame:
Baseline (Days -28 to -1) through 55.2 months (maximum observed duration)
Reported as:
Median · Months
Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment
MonthsAcalabrutinibIbrutinib
Progression-free Survival (PFS) Based on Independent Review Committee (IRC) Assessment38.4 (33.0 to 38.6)38.4 (33.0 to 41.6)
Statistical analysis
  • Acalabrutinib vs Ibrutinib · Hazard ratio (hr): 1.00 · 95% CI 0.79 to 1.27Cox Proportional Hazards model stratified by 17p deletion status (yes versus no) and number of prior therapies (1-3 versus \>=4).
SecondaryNumber of Participants With Treatment-emergent Infections Grade >= 3

Number of participants with treatment-emergent infections Grade \>=3 are reported.

Time frame:
Day 1 through 83.5 months (maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Infections Grade >= 3
ParticipantsAcalabrutinibIbrutinib
Number of Participants With Treatment-emergent Infections Grade >= 398101
SecondaryNumber of Participants With Treatment-emergent Richter's Transformation

Richter's transformation is defined as the occurrence of an aggressive lymphoma in participants with a previous or concomitant diagnosis of CLL. Richter's transformation was assessed by central pathology. Number of participants with treatment-emergent Richter's transformation are reported.

Time frame:
Day 1 through 83.5 months (maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Richter's Transformation
ParticipantsAcalabrutinibIbrutinib
Number of Participants With Treatment-emergent Richter's Transformation1314
SecondaryNumber of Participants With Treatment-emergent Atrial Fibrillation

Number of participants with treatment-emergent atrial fibrillation (including atrial flutter) are reported.

Time frame:
Day 1 through 83.5 months (maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Atrial Fibrillation
ParticipantsAcalabrutinibIbrutinib
Number of Participants With Treatment-emergent Atrial Fibrillation3249
SecondaryOverall Survival (OS)

The OS is defined as the time from date of randomization to date of death due to any cause. The OS is assessed using the Kaplan-Meier method.

Time frame:
Baseline (Days -28 to -1) through 83.7 months (maximum observed duration)
Reported as:
Median · Months
Overall Survival (OS)
MonthsAcalabrutinibIbrutinib
Overall Survival (OS)NA (NA to NA)NA (65.0 to NA)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. The TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.

Time frame:
Day 1 through 83.5 months (maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsAcalabrutinibIbrutinib
Any TEAEs262259
Any TESAEs161177
SecondaryNumber of Participants With Treatment-emergent Laboratory Abnormalities

Number of participants with treatment-emergent laboratory abnormalities are reported. Laboratory abnormality is defined as any abnormal finding during analysis of hematology and serum chemistry.

Time frame:
Day 1 through 83.5 months (maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Laboratory Abnormalities
ParticipantsAcalabrutinibIbrutinib
Absolute neutrophil count (decreased)124135
Haemoglobin (decreased)139131
Platelets (decreased)119116
Leukocytes (decreased)6064
Leukocytes (increased)6884
Absolute lymphocyte count (ALC) (decreased)6665
ALC (increased)7172
Alanine aminotransferase (increased)7370
Albumin (decreased)3144
Alkaline phosphatase (increased)6660
Aspartate aminotransferase (increased)4258
Bilirubin (increased)4669
Calcium (decreased)5671
Calcium (increased)1511
Creatinine (increased)164168
Glucose (decreased)513
Glucose (increased)2123
Phosphate (decreased)9374
Potassium (decreased)2740
Potassium (increased)6252
Sodium (decreased)2637
Sodium (increased)7046
Urate (increased)7096
SecondaryNumber of Participants With Abnormal Vital Signs Reported as TEAEs

Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal finding in the vital sign parameters (body temperature, blood pressure, heart rate, and respiratory rate).

Time frame:
Day 1 through 83.5 months (maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Vital Signs Reported as TEAEs
ParticipantsAcalabrutinibIbrutinib
Abnormal loss of weight01
Blood pressure fluctuation01
Blood pressure increased23
Blood pressure decreased10
Blood pressure systolic increased01
Body temperature decreased10
Body temperature increased01
Bradycardia31
Breath sounds abnormal01
Cardiac murmur12
Dyspnoea4027
Dyspnoea exertional25
Heart rate increased01
Heart rate irregular10
Hypertension2670
Hypotension157
Hyperpyrexia10
Orthostatic hypotension21
Palpitations1215
Pyrexia6655
Tachycardia77
Weight decreased2923
Weight increased1310
White coat hypertension01
SecondaryPercentage of Participants With Lymphocytosis

Percentage of participants with at least one occurrence of treatment-related lymphocytosis defined as an elevation in ALC of \>= 50% compared with baseline and a postbaseline assessment of \> 5000/μL in the peripheral blood are reported.

Time frame:
Day 1 through 83.5 months (maximum observed duration)
Reported as:
Number · Percentage of participants
Percentage of Participants With Lymphocytosis
Percentage of participantsAcalabrutinibIbrutinib
Percentage of Participants With Lymphocytosis72.5 (66.7 to 77.7)74.3 (68.6 to 79.5)
SecondaryNumber of Participants With Electrocardiogram (ECG) Abnormality at Baseline

Number of participants with ECG abnormality at baseline are reported.

Time frame:
Baseline (Days -28 to -1)
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Abnormality at Baseline
ParticipantsAcalabrutinibIbrutinib
Abnormal, not clinically significant8698
Abnormal, clinically significant41
SecondaryNumber of Participants With Shift From Baseline to Worst (Grade 3 and 4) Postbaseline in Eastern Cooperative Oncology Group (ECOG) Performance Status

The ECOG performance status assessed participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (\>50% of waking hours), capable of all self-care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair \>50% of waking hrs; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=death. Number of participants with shift from baseline (Days -28 to -1) to worst Grade 3 and 4 in ECOG performance status are reported.

Time frame:
Baseline (Days -28 to -1) through 83.5 months (maximum observed duration)
Reported as:
Count of participants · Participants
Number of Participants With Shift From Baseline to Worst (Grade 3 and 4) Postbaseline in Eastern Cooperative Oncology Group (ECOG) Performance Status
ParticipantsAcalabrutinibIbrutinib
Baseline=0; Postbaseline=301
Baseline=1; Postbaseline=335
Baseline=2; Postbaseline=341
Baseline=0; Postbaseline=400
Baseline=1; Postbaseline=400
Baseline=2; Postbaseline=400

Adverse events

Collected over Day 1 through 83.5 months (maximum observed duration).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Acalabrutinib89/266 (33.5%)161/266 (60.5%)251/266 (94.4%)
Ibrutinib106/263 (40.3%)177/263 (67.3%)251/263 (95.4%)
Most frequent serious events
Showing 10 of 354
Most frequent serious events
EventAcalabrutinibIbrutinib
PneumoniaInfections and infestations33/26630/263
Atrial fibrillationCardiac disorders8/26616/263
COVID-19Infections and infestations15/26614/263
AnaemiaBlood and lymphatic system disorders15/26613/263
PyrexiaGeneral disorders11/2666/263
SepsisInfections and infestations5/2667/263
Urinary tract infectionInfections and infestations3/2667/263
Cardiac failureCardiac disorders4/2666/263
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2666/263
Acute kidney injuryRenal and urinary disorders2/2666/263
Most frequent other events
Showing 10 of 69
Most frequent other events
EventAcalabrutinibIbrutinib
DiarrhoeaGastrointestinal disorders93/266122/263
HeadacheNervous system disorders92/26656/263
CoughRespiratory, thoracic and mediastinal disorders79/26660/263
Upper respiratory tract infectionInfections and infestations73/26665/263
ArthralgiaMusculoskeletal and connective tissue disorders55/26670/263
HypertensionVascular disorders26/26670/263
NeutropeniaBlood and lymphatic system disorders56/26665/263
FatigueGeneral disorders62/26648/263
PyrexiaGeneral disorders61/26650/263
AnaemiaBlood and lymphatic system disorders53/26648/263

Baseline characteristics

Intent-to-treat (ITT) population included all participants randomized and were analyzed according to the arm to which they were randomly assigned.

Age, Continuous
Age, Continuous(Years)AcalabrutinibIbrutinibTotal
Age (years)65.5 ± 9.365.3 ± 9.665.4 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)AcalabrutinibIbrutinibTotal
Sex — Female8371154
Sex — Male185194379
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AcalabrutinibIbrutinibTotal
Hispanic or Latino8513
Not Hispanic or Latino235237472
Unknown or Not Reported252348
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AcalabrutinibIbrutinibTotal
American Indian or Alaska Native000
Asian123
Native Hawaiian or Other Pacific Islander000
Black or African American5813
White257245502
More than one race000
Unknown or Not Reported51015
08

Study locations

130 sites
  • Research Site
    Phoenix, Arizona 85054, United States
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Berkeley, California 94704, United States
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    La Jolla, California 92093, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Palo Alto, California 94304, United States
  • Research Site
    Santa Rosa, California 95403, United States
  • Research Site
    Jacksonville, Florida 32224, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Athens, Georgia 30607, United States
  • Research Site
    Harvey, Illinois 60426, United States
  • Research Site
    Peoria, Illinois 61615, United States
  • Research Site
    Wichita, Kansas 67214, United States
  • Research Site
    Minneapolis, Minnesota 55426, United States
  • Research Site
    Rochester, Minnesota 55905, United States
  • Research Site
    Billings, Montana 59102, United States
  • Research Site
    Hackensack, New Jersey ?07601, United States
  • Research Site
    Lake Success, New York 11042, United States
  • Research Site
    New Hyde Park, New York 11042, United States
  • Research Site
    New York, New York 10021, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Durham, North Carolina 27710, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Round Rock, Texas 78665, United States
  • Research Site
    Charlottesville, Virginia 22908, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Northwest WA, Wisconsin 20007, United States
  • Research Site
    Darlinghurst, 2010, Australia
  • Research Site
    Frankston, 3199, Australia
  • Research Site
    Melbourne, 3000, Australia
  • Research Site
    St Leonards, 2065, Australia
  • Research Site
    Waratah NSW, 2298, Australia
  • Research Site
    Wollongong, 2500, Australia
  • Research Site
    Bruges, 8000, Belgium
  • Research Site
    Brussels, 1200, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Yvoir, 5530, Belgium
  • Research Site
    Aalborg, 9100, Denmark
  • Research Site
    Indgang 27B, DK-4000, Denmark
  • Research Site
    Bobigny, 93000, France
  • Research Site
    Créteil, 94010, France
  • Research Site
    Pierre-Bénite, 69310, France
  • Research Site
    Rennes, 35000, France
  • Research Site
    Rouen, 76038, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    München, 81241, Germany
  • Research Site
    Ulm, 89081, Germany
  • Research Site
    Budapest, 1083, Hungary
  • Research Site
    Budapest, 1122, Hungary
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Kaposvár, 7400, Hungary
  • Research Site
    Haifa, 31000, Israel
  • Research Site
    Haifa, 31096, Israel
  • Research Site
    Haifa, 34362, Israel
  • Research Site
    Jerusalem, 9103102, Israel
  • Research Site
    Nahariya, 22100, Israel
  • Research Site
    Petah Tikvah, 49102, Israel
  • Research Site
    Qiryat Krinitzi, 52621, Israel
  • Research Site
    Tiberias, 15208, Israel
  • Research Site
    Bologna, 40138, Italy
  • Research Site
    Cagliari, 9121, Italy
  • Research Site
    Cona, 44124, Italy
  • Research Site
    Florence, 50134, Italy
  • Research Site
    Meldola, 47014, Italy
  • Research Site
    Milan, 20132, Italy
  • Research Site
    Milan, 20162, Italy
  • Research Site
    Modena, 41100, Italy
  • Research Site
    Ravenna, 48121, Italy
  • Research Site
    Rome, 168, Italy
  • Research Site
    Almere Stad, 1315 RA, Netherlands
  • Research Site
    Amsterdam, 1105 AZ, Netherlands
  • Research Site
    Blaricum, 1261, Netherlands
  • Research Site
    Breda, 4818 CK, Netherlands
  • Research Site
    Delft, 2600 GA, Netherlands
  • Research Site
    Dordrecht, 3317, Netherlands
  • Research Site
    Geleen, 6162 BG, Netherlands
  • Research Site
    Groningen, 9700, Netherlands
  • Research Site
    Haarlem, 2035 RC, Netherlands
  • Research Site
    Leiden, 2333, Netherlands
  • Research Site
    Rotterdam, 3062 PA, Netherlands
  • Research Site
    Rotterdam, 3083 AN, Netherlands
  • Research Site
    Utrecht, 3584, Netherlands
  • Research Site
    Zutphens, 7207 AE, Netherlands
  • Research Site
    Addington, 8011, New Zealand
  • Research Site
    Auckland, ?0620, New Zealand
  • Research Site
    Tauranga, 3112, New Zealand
  • Research Site
    Bydgoszcz, 85-168, Poland
  • Research Site
    Gdansk, 80-129, Poland
  • Research Site
    Gdynia, 81-519, Poland
  • Research Site
    Krakow, 30-727, Poland
  • Research Site
    Lodz, 93-510, Poland
  • Research Site
    Olsztyn, 10-228, Poland
  • Research Site
    Opole, 46-020, Poland
  • Research Site
    Słupsk, 76-200, Poland
  • Research Site
    Wroclaw, 50-001, Poland

Showing the first 100 of 130 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Byrd JC, Hakre S, Ghia P. How well does acalabrutinib work and how safe is it to treat patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have had previous treatments? a plain language summary of 2 key studies. Future Oncol. 2025 Nov;21(26):3343-3357. doi: 10.1080/14796694.2025.2494976. Epub 2025 Jun 8. PubMed 40485230 ↗
  • Alfaifi A, Bahashwan S, Alsaadi M, Ageel AH, Ahmed HH, Fatima K, Malhan H, Qadri I, Almehdar H. Advancements in B-Cell Non-Hodgkin's Lymphoma: From Signaling Pathways to Targeted Therapies. Adv Hematol. 2024 Nov 12;2024:5948170. doi: 10.1155/2024/5948170. eCollection 2024. PubMed 39563886 ↗
  • Woyach JA, Jones D, Jurczak W, Robak T, Illes A, Kater AP, Ghia P, Byrd JC, Seymour JF, Long S, Mohamed N, Benrashid S, Lai TH, De Jesus G, Lai R, de Bruin G, Rule S, Munugalavadla V. Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib. Blood. 2024 Sep 5;144(10):1061-1068. doi: 10.1182/blood.2023023659. PubMed 38754046 ↗
  • Seymour JF, Byrd JC, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O'Brien S, Brown JR, Munir T, Mato A, Stilgenbauer S, Bajwa N, Miranda P, Higgins K, John E, de Borja M, Jurczak W, Woyach JA. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 2023 Aug 24;142(8):687-699. doi: 10.1182/blood.2022018818. PubMed 37390310 ↗
  • Kipps TJ. Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia. Cancer J. 2021 Jul-Aug 01;27(4):306-313. doi: 10.1097/PPO.0000000000000536. PubMed 34398557 ↗
  • Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O'Brien S, Yenerel MN, Illes A, Kay N, Garcia-Marco JA, Mato A, Pinilla-Ibarz J, Seymour JF, Lepretre S, Stilgenbauer S, Robak T, Rothbaum W, Izumi R, Hamdy A, Patel P, Higgins K, Sohoni S, Jurczak W. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. J Clin Oncol. 2021 Nov 1;39(31):3441-3452. doi: 10.1200/JCO.21.01210. Epub 2021 Jul 26. PubMed 34310172 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Sep 2020, 61 months.

Results were first posted in Jan 2022, 1 year 4 months after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 61 months is above that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2015
First posted
Jun 23, 2015
StartActual
Jul 28, 2015
Primary completionActual
Sep 15, 2020
CompletionEst.
Jan 3, 2028
Results first posted
Jan 28, 2022
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02477696
Lead sponsor
Acerta Pharma BV
Responsible party
Sponsor
First posted
Jun 23, 2015
Start date
Jul 28, 2015
Primary completion
Sep 15, 2020
Completion
Jan 3, 2028 (estimated)
Results posted
Jan 28, 2022
Last update
Aug 26, 2026

Study contacts

Acerta Clinical Trials
study director · 1-888-292-9613

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion